Sector News

Lilly shines in Japan in Q1, but CEO warns price cuts too deep

April 29, 2016
Life sciences

Eli Lilly is squarely focused on the Japanese market–its largest outside the U.S.–with John Lechleiter, chairman, president and CEO, saying growing cost cutting efforts are a concern and suggesting the policy may not aid efforts at innovation.

On the April 26 earnings call, Lechleiter told SunTrust Robinson Humphrey analyst John Boris that the price cuts this year were felt deeply.

“With respect to Japan, first of all, I’d say Lilly is well-positioned. We’ve been one of the fastest-growing–if not the fastest-growing–company in Japan now for a number of year; and these recent new product launches are keeping us on a strong trajectory there,” Lechleiter said.

But in a reference to a double-whammy on reimbursement price cuts this year in Japan, Lechleiter was not as upbeat.

A once-every-two-years price cut exercise occurred earlier this year to reach savings of $1.5 billion. As well, Japan’s Central Social Insurance Medical Council–known as Chuikyo–implemented a formula for best-selling drugs that saw reimbursement ease as much as 50% for key products.

Japanese lawmakers have also suggested annual price revisions, sending shockwaves through the foreign and domestic companies in the country.

“We are very concerned about the threat of annual repricing,” Lechleiter said.

“The industry’s been quite active in engaging with the policymakers in Japan. I myself have been engaged in that quite recently. Japan is seeing a more rapid uptake of generics; they’re ahead of the time scale for generic adoption that was initially laid out by the government. We believe that, in combination with the current biennial price decreases, puts Japan on a trajectory to keep their drug costs essentially flat for the remainder of this decade and beyond.”

Lechleiter also said that lower price won’t translate into the sweeping economic reforms sought by Prime Minister Shinzo Abe in a battle to break decades of deflation by pushing innovation policies.

“A key part of Abe’s platform has been to actually develop and grow the indigenous biopharmaceutical industry there. Part of our messaging has also included the fact that without an opportunity to realize full value from the products that we do launch there, I think the emphasis on the discovery and development of innovative new medicines in Japan is going to suffer as well.”

Lilly notched 4 new products in Japan last year, including Cyramza (ramucirumab) for gastric cancer and 3 in the diabetes area–Jardiance (empagliflozin), Trulicity (dulaglutide), and an insulin glargine biosimilar.

Overall pharma revenue in Japan gained 16% in the first quarter, up 14% in constant currency, said Phil Johnson, of Investor Relations.

But Johnson added that pharma revenue in China fell 14%, 9% on a constant-currency basis, as buying patterns changed.

By EJ Lane

Source: Fierce Pharma

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.